MedTrace Logo

Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder

NCT02673047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 474

Last updated 2016-10-24

No results posted yet for this study

Summary

This study will describe the prescription conditions of botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) or idiopathic overactive bladder (IOAB) as per standard of care in clinical practice in France.

Conditions

  • Urinary Bladder, Overactive
  • Urinary Bladder, Neurogenic

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673047 on ClinicalTrials.gov